FlahyRecovery is an AI & gene expression based immune profiling biomarker for decision support in precision oncology
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Accurate characterization of the tumor microenvironment (TME) is crucial for inferring tumor biology, subsequent tumor behavior, and predicting therapeutic response. Current characterization methods are inadequate in capturing the complexity of immune signaling networks, hindering robust clinical decision making. To address this, we have developed FlahyRecovery - an artificial intelligence (AI) and gene expression based immune profiling biomarker, implemented via a supervised classification machine learning model, that integrates response prediction and prognostic insights to personalize treatment design, particularly immunotherapy. Methods Gene expression data of 7424 tumor specimens across 14 cancers was annotated specimen wise into three immune subtypes: Elevated Immunity (Hot) with high cytotoxic T-cell infiltration, Suppressed Immunity (Cold) marked by immune exclusion and stromal dominance, and Moderate Immunity (Intermediate) exhibiting mixed features. Following annotation validation, an AI model was trained and tested on the annotated data to classify new tumor specimens into the three immune subtypes: Elevated Immunity (Hot), Suppressed Immunity (Cold) and Moderate Immunity (Intermediate) based on the expression of a panel of 1275 genes involved in immune cell signaling and immune signal transduction. Results In a multi-tumor validation cohort (N=1337), the subtyping model showed a sensitivity of 79%, a specificity of 89%, and a one-vs-rest AUC of 0.93. Elevated Immunity tumors correlated with prolonged survival and immunotherapy response, while Suppressed Immunity tumors correlated with treatment resistance and need for combination therapy. Conclusion Artificial intelligence can be effectively used to process tumor biology digitized via next-generation sequencing, to accurately mark the TME from an immunological perspective. Its clinical utility mechanisms andying patients who can benefit from immunotherapies, identifying treatment resistance mechanisms, and informing combination treatment regimes. Keywords: Artificial Intelligence (AI), Tumor Microenvironment, Next-Generation Sequencing, Subtyping, Algorithm, Metrics, Precision Medicine